title: Long-term observation of endocrine ophthalmopathy and retrospective appraisal of therapeutic measures.
abstract: The course of endocrine ophthalmopathy was investigated on the basis of clinical and biochemical parameters and in relation to different therapeutic strategies. A retrospective appraisal was made of 297 patients (44 +/- 14 yr, 249 women) with inclusion of anamnestic and clinical data as well as the results of computer tomography. At the beginning of therapy, 253 patients were hyperthyroid, 36 were euthyroid and eight were hypothyroid. The HLA typing carried out in 89 patients showed the phenotypes B8 and DR3 in 32% and 42% of the cases, respectively. Raised microsomal antibodies were present in 56% of the patients and there were raised thyroglobulin antibodies in 19%. Sixty-three % of the patients received immunosuppressants in the course of therapy: glucocorticoids in all cases, nonsteroid immunosuppressants in 15%. Eight % of the patients were irradiated retrobulbarly. The inflammatory parameters could be favorably affected, whereas eye muscle involvement and bulbar protrusion proved to be more resistant to therapy. In patients with combined immunosuppressant therapy or steroids + retrobulbar radiation, there were unequivocal successes with regard to the proptosis, vision and intraocular pressure. None of the strategies applied constitutes an optimal treatment with regard to the long-term course. Following therapy, there is an improvement of endocrine ophthalmopathy, but not complete healing.
authors.affiliation: III Department of Medicine, Endocrinology and Metabolism, Johannes Gutenberg University Hospital, Mainz, FRG.
authors.forename: G
authors.initials: G
authors.lastname: Kahaly
authors.forename: H
authors.initials: H
authors.lastname: Böckmann
authors.forename: J
authors.initials: J
authors.lastname: Beyer
authors.forename: S
authors.initials: S
authors.lastname: Bischoff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000453:epidemiology*; D003524:Cyclosporins / Q000627:therapeutic use; D004700:Endocrine System Diseases / Q000150:complications*; D005094:Exophthalmos / Q000473:pathology / Q000503:physiopathology; D005123:Eye / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D005128:Eye Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014786:Vision Disorders / Q000473:pathology / Q000503:physiopathology; D014785:Vision, Ocular / Q000502:physiology
chemical_list: D003524:Cyclosporins; D005938:Glucocorticoids; D011241:Prednisone